Fulcrum rises after BofA upgrades rating on chance of FSHD study success by Technical Terrence Team 09/09/2024 0 Fulcrum Therapeutics (NASDAQ:FULC) Shares rose more than 5% after BofA upgraded ratings to Neutral, citing the likelihood of success of ...